{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:41:47Z","timestamp":1790041307059,"version":"4.0.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.arcmed.2014.11.001","type":"journal-article","created":{"date-parts":[[2014,11,11]],"date-time":"2014-11-11T17:03:45Z","timestamp":1415725425000},"page":"589-595","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"title":["Oral Coenzyme Q10 Supplementation in Patients with Nonalcoholic Fatty Liver Disease: Effects on Serum Vaspin, Chemerin, Pentraxin 3, Insulin Resistance and Oxidative Stress"],"prefix":"10.1016","volume":"45","author":[{"given":"Mahdieh Abbasalizad","family":"Farhangi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beytollah","family":"Alipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elnaz","family":"Jafarvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manouchehr","family":"Khoshbaten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl","key":"10.1016\/j.arcmed.2014.11.001_bib1","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1194\/jlr.R800089-JLR200","article-title":"Nonalcoholic fatty liver disease","volume":"50","author":"Erickson","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.arcmed.2014.11.001_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2161-1017.1000e117","article-title":"Chemerin in non-alcoholic fatty liver disease? Up or down?","volume":"2","author":"Buechler","year":"2013","journal-title":"Endocrinol Metab Syndr"},{"issue":"suppl","key":"10.1016\/j.arcmed.2014.11.001_bib3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/hep.20973","article-title":"Nonalcoholic fatty liver disease: from steatosis to cirrhosis","volume":"43","author":"Farrell","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.arcmed.2014.11.001_bib4","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/hep.20466","article-title":"Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity","volume":"40","author":"Browning","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.arcmed.2014.11.001_bib5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","article-title":"The natural history of non-alcoholic fatty liver disease: a population-based cohort study","volume":"129","author":"Adams","year":"2005","journal-title":"Gastroenterology"},{"issue":"suppl","key":"10.1016\/j.arcmed.2014.11.001_bib6","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1440-1746.2010.06548.x","article-title":"Nonalcoholic fatty liver in Asia: firmly entrenched and rapidly gaining ground","volume":"26","author":"Chitturi","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.arcmed.2014.11.001_bib7","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1365-2036.2007.03586.x","article-title":"Adipokines and cytokines in non-alcoholic fatty liver disease","volume":"27","author":"Jarrar","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.arcmed.2014.11.001_bib8","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.yexmp.2013.07.009","article-title":"Chemerin is highly expressed in hepatocytes and is induced in non-alcoholic steatohepatitis liver","volume":"95","author":"Krautbauer","year":"2013","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.arcmed.2014.11.001_bib9","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20081736","article-title":"Chemerin reveals its chimeric nature","volume":"205","author":"Yoshimura","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.arcmed.2014.11.001_bib10","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.bbrc.2007.08.104","article-title":"Chemerin: a new adipokine that modulates adipogenesis via its own receptor","volume":"362","author":"Roh","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.arcmed.2014.11.001_bib11","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.febslet.2008.01.023","article-title":"Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes","volume":"582","author":"Takahashi","year":"2008","journal-title":"FEBS Lett"},{"key":"10.1016\/j.arcmed.2014.11.001_bib12","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1530\/EJE-13-0112","article-title":"Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease","volume":"169","author":"Docke","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2014.11.001_bib13","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.metabol.2010.05.008","article-title":"Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease","volume":"60","author":"Aktas","year":"2011","journal-title":"Metabolism"},{"key":"10.1016\/j.arcmed.2014.11.001_bib14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.atherosclerosis.2011.03.026","article-title":"Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease","volume":"217","author":"Yilmaz","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arcmed.2014.11.001_bib15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/00365520903443852","article-title":"Serum chemerin and vaspin in non-alcoholic fatty liver disease","volume":"45","author":"Kukla","year":"2010","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.arcmed.2014.11.001_bib16","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/07315724.2001.10719063","article-title":"Biochemical functions of coenzyme Q10","volume":"20","author":"Crane","year":"2001","journal-title":"J Am Coll Nutr"},{"key":"10.1016\/j.arcmed.2014.11.001_bib17","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.bcp.2009.07.008","article-title":"Coenzyme Q10 supplementation lowers hepatic oxidative stress and inflammation associated with diet-induced obesity in mice","volume":"78","author":"Sohet","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.arcmed.2014.11.001_bib18","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ijo.2008.265","article-title":"Coadministration of coenzyme Q prevents rosiglitazone-induced adipogenesis in ob\/ob mice","volume":"33","author":"Carmona","year":"2009","journal-title":"Int J Obes"},{"key":"10.1016\/j.arcmed.2014.11.001_bib19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/biof.5520320121","article-title":"Functions of coenzyme Q10 in inflammation and gene expression","volume":"32","author":"Schmelzer","year":"2008","journal-title":"Biofactors"},{"key":"10.1016\/j.arcmed.2014.11.001_bib20","first-page":"15","article-title":"Role of coenzyme Q10, metformin and rosiglitazone in treatment of experimental nonalcoholic steatohepatitis in rats","volume":"3","author":"El-Hamid","year":"2008","journal-title":"Tanta Med Sc J"},{"key":"10.1016\/j.arcmed.2014.11.001_bib21","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.3390\/ijms13021644","article-title":"Coenzyme Q metabolism is disturbed in high fat diet-induced nonalcoholic fatty liver disease in rats","volume":"13","author":"Bravo","year":"2012","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.arcmed.2014.11.001_bib22","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.yrtph.2005.12.002","article-title":"Safety assessment of coenzyme Q10 in healthy subjects: a double-blind, randomized, placebo-controlled trial","volume":"44","author":"Ikematsu","year":"2006","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.arcmed.2014.11.001_bib23","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.yrtph.2006.05.006","article-title":"Risk assessment for coenzyme Q10","volume":"45","author":"Hathcock","year":"2006","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.arcmed.2014.11.001_bib24","unstructured":"Hidaka T, Fujii K, Funahashi I, et\u00a0al. Overview of safety assessment ofcoenzyme Q10: animal and human data. The 5th Conference of the International CoQ10 Association, 2007 Nov 9\u201312; Kobe, Japan."},{"key":"10.1016\/j.arcmed.2014.11.001_bib25","unstructured":"World Health Organization (WHO). Waist circumference and waist-hip ratio. Report of a WHO expert consultation, Geneva: 8\u201311 December\u00a02008."},{"key":"10.1016\/j.arcmed.2014.11.001_bib26","unstructured":"International Physical Activity Questionnaire (IPAQ) guidelines for data processing and analysis of the international physical activity questionnaire. November 2005. Available from: http:\/\/www.ipaq.ki.se\/scoring.pdf."},{"key":"10.1016\/j.arcmed.2014.11.001_bib27","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1053\/gast.2002.36572","article-title":"AGA technical review on nonalcoholic fatty liver disease","volume":"123","author":"Sanyal","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.arcmed.2014.11.001_bib28","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.arcmed.2014.11.001_bib29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/adc.2003.036467","article-title":"Prevalence of the insulin resistance syndrome in obesity","volume":"90","author":"Viner","year":"2005","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.arcmed.2014.11.001_bib30","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0003-2697(78)90342-1","article-title":"Determination of malonaldehyde precursor in tissues by thiobarbituric acid test","volume":"86","author":"Mihara","year":"1978","journal-title":"Anal Biochem"},{"key":"10.1016\/j.arcmed.2014.11.001_bib31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-511X-13-22","article-title":"Coenzyme Q10 supplementation improves metabolic parameters, liver function and mitochondrial respiration in rats with high doses of atorvastatin and a cholesterol-rich diet","volume":"13","author":"Jimenez-Santos","year":"2014","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.arcmed.2014.11.001_bib32","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/sj.ejcn.1601464","article-title":"Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes","volume":"56","author":"Hodgson","year":"2002","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.arcmed.2014.11.001_bib33","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/ars.2010.3350","article-title":"Coenzyme Q as an antiadipogenic factor","volume":"14","author":"Bour","year":"2011","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.arcmed.2014.11.001_bib34","first-page":"e13658","article-title":"The effect of co-enzyme Q10 on acute liver damage in rats: a biochemical and pathological study","volume":"13","author":"Esfahani","year":"2013","journal-title":"Hepat Mon"},{"key":"10.1016\/j.arcmed.2014.11.001_bib35","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.nut.2011.06.004","article-title":"Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with coronary artery disease","volume":"28","author":"Lee","year":"2012","journal-title":"Nutrition"},{"key":"10.1016\/j.arcmed.2014.11.001_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1874387001004010001","article-title":"Coenzyme Q10 supplementation decreases oxidative stress and improves physical performance in young swimmers: a pilot study","volume":"4","author":"Leelarungrayub","year":"2010","journal-title":"Open Sports Med J"},{"key":"10.1016\/j.arcmed.2014.11.001_bib37","first-page":"46","article-title":"Effect of short-term coenzyme Q10 supplementation on oxidative stress index and total antioxidant capacity of serum in inactive men","volume":"34","author":"Rostami","year":"2012","journal-title":"Med J Tabriz Univ Med Sci"},{"key":"10.1016\/j.arcmed.2014.11.001_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1550-2783-5-8","article-title":"Effects of acute and 14-day coenzyme Q10 supplementation on exercise performance in both trained and untrained individuals","volume":"5","author":"Cooke","year":"2008","journal-title":"J Int Soc Sports Nutr"},{"key":"10.1016\/j.arcmed.2014.11.001_bib39","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1089\/jmf.2010.1202","article-title":"Effects of coenzyme Q10 on arterial stiffness, metabolic parameters, and fatigue in obese subjects: a double-blind randomized controlled study","volume":"14","author":"Lee","year":"2011","journal-title":"J Med Food"},{"key":"10.1016\/j.arcmed.2014.11.001_bib40","first-page":"1103","article-title":"The coenzyme Q10 supplementation effects on lipid profile, fasting blood sugar, blood pressure and oxidative stress status among non-alcoholic fatty liver disease patients: a randomized, placebo-controlled, pilot study","volume":"3","author":"Mohammadshahi","year":"2014","journal-title":"J Gastroentrol Hepatic Res"},{"key":"10.1016\/j.arcmed.2014.11.001_bib41","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1517\/13543784.17.3.327","article-title":"Vaspin: a new serpin with insulin sensitizing effects","volume":"17","author":"Wada","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.arcmed.2014.11.001_bib42","first-page":"2530","article-title":"Serum vaspin level in relation to postprandial plasma glucose concentration in subjects with diabetes","volume":"122","author":"Yin","year":"2009","journal-title":"Chin Med J"},{"key":"10.1016\/j.arcmed.2014.11.001_bib43","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.2337\/db08-0127","article-title":"Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance","volume":"57","author":"Tan","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.arcmed.2014.11.001_bib44","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1161\/01.CIR.102.6.636","article-title":"PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans","volume":"102","author":"Peri","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.arcmed.2014.11.001_bib45","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10238-009-0039-z","article-title":"Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile","volume":"9","author":"Zanetti","year":"2009","journal-title":"Clin Exp Med"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440914002227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440914002227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:42:59Z","timestamp":1759261379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440914002227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0188440914002227"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2014.11.001","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral Coenzyme Q10 Supplementation in Patients with Nonalcoholic Fatty Liver Disease: Effects on Serum Vaspin, Chemerin, Pentraxin 3, Insulin Resistance and Oxidative Stress","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2014.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 IMSS. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}